Lyell Immunopharma’s (LYEL) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Lyell Immunopharma (NASDAQ:LYEL) in a research report report published on Tuesday,Benzinga reports. HC Wainwright currently has a $1.00 price objective on the stock.

Separately, Bank of America downgraded Lyell Immunopharma from a “buy” rating to an “underperform” rating and cut their target price for the stock from $6.00 to $1.00 in a research report on Wednesday, October 30th.

Lyell Immunopharma Stock Performance

LYEL opened at $1.10 on Tuesday. The stock’s 50 day simple moving average is $1.21 and its 200-day simple moving average is $1.68. The stock has a market cap of $307.14 million, a PE ratio of -1.39 and a beta of -0.47. Lyell Immunopharma has a 1 year low of $0.85 and a 1 year high of $3.26.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. The business had revenue of $0.03 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. Equities analysts forecast that Lyell Immunopharma will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of hedge funds have recently made changes to their positions in LYEL. Centiva Capital LP bought a new stake in shares of Lyell Immunopharma during the third quarter worth $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Lyell Immunopharma during the 3rd quarter worth about $52,000. Intech Investment Management LLC bought a new stake in Lyell Immunopharma in the third quarter valued at approximately $52,000. Dimensional Fund Advisors LP increased its position in shares of Lyell Immunopharma by 197.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock valued at $58,000 after buying an additional 26,635 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Lyell Immunopharma in the first quarter worth about $64,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.